Joint EMA/FDA/MHLW-PMDA orphan medicinal product workshop takes place today
A workshop on orphan product designation and grants is taking place today at the European Medicines Agency (EMA), jointly organised by the EMA, the US Food and Drug Administration (FDA) and for the first time the Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA).
You can follow a live broadcast of the plenary session of the workshop by clicking on the ‘multimedia’ tab on the event page.
The aim of the workshop is to provide information to companies as well as academics on the EMA, FDA and MHLW-PMDA systems for orphan medicine designation and on the grant programmes available for the development of orphan medicines. These programmes aim to promote the development of new medicines for the treatment of rare diseases.